|
1
|
Backman M, La Fleur L, Kurppa P,
Djureinovic D, Elfving H, Brunnstrom H, Mattsson JSM, Lindberg A,
Ponten V, Eltahir M, et al: Infiltration of NK and plasma cells is
associated with a distinct immune subset in non-small cell lung
cancer. J Pathol. 255:245–256. 2021. View Article : Google Scholar
|
|
2
|
Park K, Haura EB, Leighl NB, Mitchell P,
Shu CA, Girard N, Viteri S, Han JY, Kim SW, Lee CK, et al:
Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung
cancer progressing on platinum chemotherapy: Initial results from
the CHRYSALIS phase I study. J Clin Oncol. 39:3391–3402. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mielgo-Rubio X, Martín M, Remon J, Higuera
O, Calvo V, Jarabo JR, Conde E, Luna J, Provencio M, De Castro J,
et al: Targeted therapy moves to earlier stages of non-small-cell
lung cancer: Emerging evidence, controversies and future
challenges. Future Oncol. 17:4011–4025. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu Z, Sun D, Zhu Q and Liu X: The
screening of immune-related biomarkers for prognosis of lung
adenocarcinoma. Bioengineered. 12:1273–1285. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ye Q, Putila J, Raese R, Dong C, Qian Y,
Dowlati A and Guo NL: Identification of prognostic and
chemopredictive microRNAs for non-small-cell lung cancer by
integrating SEER-medicare data. Int J Mol Sci. 22:76582021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhu X, Kudo M, Huang X, Sui H, Tian H,
Croce CM and Cui R: Frontiers of microRNA signature in non-small
cell lung cancer. Front Cell Dev Biol. 9:6439422021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hou J, Meng F, Chan LW, Cho WC and Wong
SC: Circulating plasma microRNAs as diagnostic markers for NSCLC.
Front Genet. 7:1932016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li Y, Chen P, Zu L, Liu B, Wang M and Zhou
Q: MicroRNA-338-3p suppresses metastasis of lung cancer cells by
targeting the EMT regulator Sox4. Am J Cancer Res. 6:127–140.
2016.PubMed/NCBI
|
|
9
|
Peng LP: Regarding: MicroRNA-126 targeting
PIK3R2 inhibits NSCLC A549 cell proliferation, migration, and
invasion by regulation of PTEN/PI3K/AKT pathway. Clin Lung Cancer.
22:e446–e450. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Han Y, Liu D and Li L: PD-1/PD-L1 pathway:
Current researches in cancer. Am J Cancer Res. 10:727–742.
2020.PubMed/NCBI
|
|
11
|
Cha JH, Chan LC, Li CW, Hsu JL and Hung
MC: Mechanisms controlling PD-L1 expression in cancer. Mol Cell.
76:359–370. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Peng S, Wang R, Zhang X, Ma Y, Zhong L, Li
K, Nishiyama A, Arai S, Yano S and Wang W: EGFR-TKI resistance
promotes immune escape in lung cancer via increased PD-L1
expression. Mol Cancer. 18:1652019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang Z, Su W, Lu T, Wang Y, Dong Y, Qin
Y, Liu D, Sun L and Jiao W: First-line immune-checkpoint inhibitors
in non-small cell lung cancer: Current landscape and future
progress. Front Pharmacol. 11:5780912020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang B, Zhao H, Zhao L, Zhang Y, Wan Q,
Shen Y, Bu X, Wan M and Shen C: Up-regulation of OLR1 expression by
TBC1D3 through activation of TNFα/NF-κB pathway promotes the
migration of human breast cancer cells. Cancer Lett. 408:60–70.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Patel R, Brzezinska EA, Repiscak P, Ahmad
I, Mui E, Gao M, Blomme A, Harle V, Tan EH, Malviya G, et al:
Activation of β-catenin cooperates with loss of pten to drive
AR-independent castration-resistant prostate cancer. Cancer Res.
80:576–590. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu J, Liu D, Sun X, Yang K, Yao J, Cheng
C, Wang C and Zheng J: CDX2 inhibits the proliferation and tumor
formation of colon cancer cells by suppressing Wnt/β-catenin
signaling via transactivation of GSK-3β and Axin2 expression. Cell
Death Dis. 10:262019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rotoli D, Santana-Viera L, Ibba ML,
Esposito CL and Catuogno S: Advances in oligonucleotide aptamers
for NSCLC targeting. Int J Mol Sci. 21:60752020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Horvath L, Thienpont B, Zhao L, Wolf D and
Pircher A: Overcoming immunotherapy resistance in non-small cell
lung cancer (NSCLC)-novel approaches and future outlook. Mol
Cancer. 19:1412020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liang G, Meng W, Huang X, Zhu W, Yin C,
Wang C, Fassan M, Yu Y, Kudo M, Xiao S, et al: miR-196b-5p-mediated
downregulation of TSPAN12 and GATA6 promotes tumor progression in
non-small cell lung cancer. Proc Natl Acad Sci USA. 117:4347–4357.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xiao H: MiR-7-5p suppresses tumor
metastasis of non-small cell lung cancer by targeting NOVA2. Cell
Mol Biol Lett. 24:602019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang BM, Zhao JR, Huo TT, Zhang ML and Wu
XH: MiR-20a lowers chemosensitivity of liver cancer Huh-7 cells via
regulating NF-кB expression. Eur Rev Med Pharmacol Sci.
24:11569–11577. 2020.PubMed/NCBI
|
|
22
|
Shi KY, Fan LY, Xu D, Ren LP, Wang LP,
Chen LY and Wang LJ: MiR-20a suppresses proliferation and
facilitates apoptosis of breast cancer cells via the MTOR signaling
pathway. Eur Rev Med Pharmacol Sci. 24:11650–11657. 2020.PubMed/NCBI
|
|
23
|
He Y, Ma H, Wang J, Kang Y and Xue Q:
miR-20a-5p inhibits endometrial cancer progression by targeting
janus kinase 1. Oncol Lett. 21:4272021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li J, Ye D, Shen P, Liu X, Zhou P, Zhu G,
Xu Y, Fu Y, Li X, Sun J, et al: Mir-20a-5p induced WTX deficiency
promotes gastric cancer progressions through regulating PI3K/AKT
signaling pathway. J Exp Clin Cancer Res. 39:2122020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chaniad P, Trakunran K, Geater SL,
Keeratichananont W, Thongsuksai P and Raungrut P: Serum miRNAs
associated with tumor-promoting cytokines in non-small cell lung
cancer. PLoS One. 15:e02415932020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yi M, Niu M, Xu L, Luo S and Wu K:
Regulation of PD-L1 expression in the tumor microenvironment. J
Hematol Oncol. 14:102021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hsu PC, Jablons DM, Yang CT and You L:
Epidermal growth factor receptor (EGFR) pathway, yes-associated
protein (YAP) and the regulation of programmed death-ligand 1
(PD-L1) in non-small cell lung cancer (NSCLC). Int J Mol Sci.
20:38212019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang H, Shan Q, Guo J, Han X, Zhao C, Li H
and Wang Z: PDL1 high expression without TP53, KEAP1 and EPHA5
mutations could better predict survival for patients with NSCLC
receiving atezolizumab. Lung Cancer. 151:76–83. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brody R, Zhang Y, Ballas M, Siddiqui MK,
Gupta P, Barker C, Midha A and Walker J: PD-L1 expression in
advanced NSCLC: Insights into risk stratification and treatment
selection from a systematic literature review. Lung Cancer.
112:200–215. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xie P, Peng Z, Chen Y, Li H, Du M, Tan Y,
Zhang X, Lu Z, Cui CP, Liu CH, et al: Neddylation of PTEN regulates
its nuclear import and promotes tumor development. Cell Res.
31:291–311. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dastmalchi N, Hosseinpourfeizi MA,
Khojasteh SMB, Baradaran B and Safaralizadeh R: Tumor suppressive
activity of miR-424-5p in breast cancer cells through targeting
PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway. Life
Sci. 259:1182392020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rennier K, Shin WJ, Krug E, Virdi G and
Pachynski RK: Chemerin reactivates PTEN and suppresses PD-L1 in
tumor cells via modulation of a novel CMKLR1-mediated signaling
cascade. Clin Cancer Res. 26:5019–5035. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lamberti G, Sisi M, Andrini E, Palladini
A, Giunchi F, Lollini PL, Ardizzoni A and Gelsomino F: The
mechanisms of PD-L1 regulation in non-small-cell lung cancer
(NSCLC): Which are the involved players? Cancers (Basel).
12:31292020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Du L, Lee JH, Jiang H, Wang C, Wang S,
Zheng Z, Shao F, Xu D, Xia Y, Li J, et al: β-Catenin induces
transcriptional expression of PD-L1 to promote glioblastoma immune
evasion. J Exp Med. 217:e201911152020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Song C, Xiong G, Yang S, Wei X, Ye X,
Huang W and Zhang R: PRDX1 stimulates non-small-cell lung carcinoma
to proliferate via the Wnt/β-catenin signaling. Panminerva Med. Sep
3–2020.(Epub ahead of print). View Article : Google Scholar
|
|
36
|
He S and Tang S: WNT/β-catenin signaling
in the development of liver cancers. Biomed Pharmacother.
132:1108512020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Trujillo JA, Luke JJ, Zha Y, Segal JP,
Ritterhouse LL, Spranger S, Matijevich K and Gajewski TF: Secondary
resistance to immunotherapy associated with β-catenin pathway
activation or PTEN loss in metastatic melanoma. J Immunother
Cancer. 7:2952019. View Article : Google Scholar : PubMed/NCBI
|
